Back at the big JP Morgan conference in San Francisco in January, Roche's big $1 billion-plus tie-up with Foundation Medicine made it clear to the most casual biopharma observer that the pharma giant plans to partner more frequently as it builds up its pipeline and expands on its diagnostics business.
With a bunch of biologic drugs in development, Roche's Genentech sees the need for more production capacity. To meet it, the biotech is expanding a fill/finish facility in Oregon, investing more than $100 million on the project and adding dozens of jobs there.
Roche's Genentech subsidiary is embarking on a $125 million project that will take Roche's investment in biologics production to over $1 billion and add 100 more jobs to the 500 Roche initially said its biologics expansion would create.
A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
In a small study, an early-stage Parkinson's treatment from partners Prothena and Roche reduced levels of a protein with ties to the memory-destroying disease, sending the former company's shares up about 40%.
Roche inked an exclusive global deal with Sigma-Aldrich to market and distribute its biochemical reagents portfolio. Under the terms of the deal, Sigma-Aldrich will present and distribute Roche's kits and enzymes for cellular analysis, proteomics and conventional PCR applications.
Novartis and Roche can wash their hands of some kickback accusations. A federal judge tossed a long-standing whistleblower suit Tuesday, nixing allegations that the two drugmakers used kickbacks and off-label promotions to pump up sales of their asthma drug Xolair.
Natco Pharma won another battle in its quest to knock down patent barriers to its generic drugs, this time for a version of the Gilead Sciences' influenza treatment, Tamiflu (oseltamivir).
Roche handled hazardous chemicals at its now-shuttered facility in Nutley, NJ--and its neighbors say the company didn't do it properly.
There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb, Merck, AstraZeneca and Roche are speeding ahead with their research in the field, with Sanofi, Novartis and Pfizer racing to catch up.